ArticleScientific reports2020
Competing Risk Analyses of Medullary Carcinoma of Breast in Comparison to Infiltrating Ductal Carcinoma.
Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Prognostic Associations Between Adjuvant Chemotherapy and Survival in T1b-T2N0M0 Medullary Breast Cancer: A Population-Based Study of 2343 Patients.Annals of surgical oncology · 2026Article
- Survival outcomes by molecular subtypes based on receptor status in medullary breast carcinoma: a SEER database analysis.Translational cancer research · 2026Article
- Clinicopathological observation and prognostic factors of invasive breast cancer with medullary in Xinjiang.BMC medical informatics and decision making · 2025Article
- Identification of B cell antigens in solid cancer: initial insights and functional implications.Frontiers in immunology · 2025Review
- Comparison of the prognosis of medullary breast carcinoma and invasive ductal carcinoma: a SEER-based study.Translational cancer research · 2024Article
- Unveiling the Link Between Breast Cancer Treatment and Osteoporosis: Implications for Anticancer Therapy and Bone Health.BioMed research international · 2024Review
- Clinical implications of forkhead box M1, cyclooxygenase-2World journal of clinical cases · 2023Article
- A new prognostic model of esophageal squamous cell carcinoma based on Cloud-least squares support vector machine.Journal of thoracic disease · 2023Article
- A Competing Risk Model Nomogram to Predict the Long-Term Prognosis of Lung Carcinoid.Annals of surgical oncology · 2023Article
- A risk stratification model to predict chemotherapy benefit in medullary carcinoma of the breast: a population-based SEER database.Scientific reports · 2023Article
- Recognizing invasive breast carcinoma of no special type with medullary pattern.Radiology case reports · 2023Article
- Prognosis and effectiveness of chemotherapy for medullary breast carcinoma.Breast cancer research and treatment · 2022Article
- Competing-risks nomograms for predicting cause-specific mortality in parotid-gland carcinoma: A population-based analysis.Cancer medicine · 2021Article
- Hormone Receptor Status May Impact the Survival Benefit Between Medullary Breast Carcinoma and Atypical Medullary Carcinoma of the Breast: A Population-Based Study.Frontiers in oncology · 2021Article
- The Role of Adjuvant Chemotherapy in Metaplastic Breast Carcinoma: A Competing Risk Analysis of the SEER Database.Frontiers in oncology · 2021Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of current study was to use competing risk model to assess whether medullary carcinoma of the breast (MCB) has a better prognosis than invasive ductal carcinomas of breast cancer (IDC), and to build a competing risk nomogram for predicting the risk of death of MCB. We involved 3,580 MCB patients and 319,566 IDC patients from Surveillance, Epidemiology, and End Results (SEER) database. IDC was found to have a worse BCSS than MCB (Hazard ratio (HR) > 1, p < 0.001). The 5-year cumulative incidences of death (CID) was higher in IDC than MCB (p < 0.001). Larger tumor size, increasing number of positive lymph nodes and unmarried status were found to worsen the BCSS of MCB (HR > 1, p < 0.001). We found no association between ER, PR, radiotherapy or chemotherapy and MCB prognosis (p > 0.05). After a penalized variable selection process, the SH model-based nomogram showed moderate accuracy of prediction by internal validation of discrimination and calibration with 1,000 bootstraps. In summary, MCB patients had a better prognosis than IDC patients. Interestingly, unmarried status in addition to expected risk factors such as larger tumor size and increasing number of positive lymph nodes were found to worsen the BCSS of MCB. We also established a competing risk nomogram as an easy-to-use tool for prognostic estimation of MCB patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.